BI Asset Management Fondsmaeglerselskab A S Grows Stock Position in Elevance Health, Inc. $ELV

BI Asset Management Fondsmaeglerselskab A S boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 11.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 145,408 shares of the company’s stock after acquiring an additional 15,294 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned 0.07% of Elevance Health worth $44,365,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Physician Wealth Advisors Inc. grew its holdings in shares of Elevance Health by 331.6% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock worth $26,000 after purchasing an additional 63 shares during the period. Activest Wealth Management lifted its position in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its stake in Elevance Health by 94.9% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock worth $30,000 after buying an additional 37 shares during the period. BOK Financial Private Wealth Inc. acquired a new stake in shares of Elevance Health during the second quarter valued at about $32,000. Finally, Motco raised its stake in shares of Elevance Health by 334.8% in the 3rd quarter. Motco now owns 100 shares of the company’s stock valued at $32,000 after acquiring an additional 77 shares during the period. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ELV shares. Wall Street Zen raised shares of Elevance Health from a “hold” rating to a “buy” rating in a research report on Saturday, January 31st. The Goldman Sachs Group started coverage on Elevance Health in a research note on Tuesday, October 14th. They set a “neutral” rating and a $343.00 price target on the stock. Wolfe Research set a $425.00 price objective on Elevance Health and gave the company an “outperform” rating in a research note on Thursday, January 8th. Leerink Partners boosted their price objective on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday, January 29th. Finally, Guggenheim lowered their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating for the company in a report on Thursday, January 29th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Elevance Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Stock Up 0.5%

Shares of NYSE ELV opened at $340.34 on Thursday. The stock has a market cap of $75.64 billion, a P/E ratio of 13.55, a PEG ratio of 1.89 and a beta of 0.50. The business’s fifty day simple moving average is $352.02 and its 200-day simple moving average is $329.67. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75. The company has a current ratio of 1.54, a quick ratio of 1.56 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion for the quarter, compared to the consensus estimate of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.Elevance Health’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Tuesday, March 10th. Elevance Health’s payout ratio is presently 27.23%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.